Assessment of Steatosis and Fibrosis in Liver Transplant Recipients Using Controlled Attenuation Parameter and Liver Stiffness Measurements

Table 7

Univariate and multivariate analysis of predictors of moderate fibrosis.

Variables	Univariate		Multivariate
	OR (95% CI)	value	OR (95% CI)	value
Age at LT, years	0.99 (0.96–1.02)	0.521
Age at TE, years	1.00 (0.97–1.03)	0.972
Donor age, years	1.01 (0.98–1.02)	0.535
Gender (female ref.)	0.96 (0.51–1.84)	0.925
Cause of liver disease, % (n)
Autoimmune liver disease	0.52 (0.20–1.35)	0.180
Alcoholic liver disease	1.54 (0.81–2.92)	0.188
HCV	0.41 (0.07–2.30)	0.310
Others	1.05 (0.58–1.90)	0.866
BMI, kg/m^2	1.02 (0.93–1.11)	0.692
Donors BMI, kg/m^2	1.05 (0.97–1.14)	0.212
Hypertension, % (n)	2.15 (1.15–4.04)	0.017
Diabetes, % (n)	1.28 (0.70–2.36)	0.426
Thrombocytes x10^9/L	0.99 (0.98–1.01)	0.844
Glucose, mmol/L	1.11 (0.96–1.28)	0.171
Total bilirubin, mmol/L	1.01 (0.98–1.04)	0.433
ALT, U/L	1.02 (1.01–1.03)	0.019	1.01 (0.97–1.03)	0.717
AST, U/L	1.02 (1.01–1.04)	0.013	1.01 (0.98–1.02)	0.937
GGT, U/L	1.02 (1.01–1.03)	0.001	1.03 (1.01–1.05)	0.001
Triglyceride, mmol/L	1.34 (0.92–1.94)	0.126
Total cholesterol, mmol/L	0.91 (0.69–1.20)	0.495
LDL, mmol/L	0.77 (0.55–1.07)	0.125
HDL, mmol/L	1.15 (0.52–2.54)	0.726
CRP, mg/L	0.98 (0.94–1.02)	0.325
CAP, db/m	1.02 (1.01–1.03)	0.003	1.08 (1.02–1.15)	0.010
Time from LT to TE, years	1.15 (1.02–1.30)	0.024	1.06 (0.92–1.22)	0.403

LT, liver transplantation; NAFLD, nonalcoholic fatty liver disease; HCV, hepatitis C virus infection; BMI, body mass index; AST, serum aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; CRP, C-reactive protein; CAP, controlled attenuation parameter; TE, transient elastography.